SI2861223T1 - Sestavki in postopki za transmukozalno absorpcijo - Google Patents

Sestavki in postopki za transmukozalno absorpcijo

Info

Publication number
SI2861223T1
SI2861223T1 SI201332010T SI201332010T SI2861223T1 SI 2861223 T1 SI2861223 T1 SI 2861223T1 SI 201332010 T SI201332010 T SI 201332010T SI 201332010 T SI201332010 T SI 201332010T SI 2861223 T1 SI2861223 T1 SI 2861223T1
Authority
SI
Slovenia
Prior art keywords
compositions
methods
transmucosal absorption
transmucosal
absorption
Prior art date
Application number
SI201332010T
Other languages
English (en)
Inventor
Harry Brittain
Seth Lederman
Giorgio Reiner
Original Assignee
Tonix Pharma Holdings Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tonix Pharma Holdings Limited filed Critical Tonix Pharma Holdings Limited
Publication of SI2861223T1 publication Critical patent/SI2861223T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
SI201332010T 2012-06-15 2013-06-14 Sestavki in postopki za transmukozalno absorpcijo SI2861223T1 (sl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261660593P 2012-06-15 2012-06-15
US201261667774P 2012-07-03 2012-07-03
US201261725402P 2012-11-12 2012-11-12
US201361792900P 2013-03-15 2013-03-15
PCT/US2013/046023 WO2013188847A1 (en) 2012-06-15 2013-06-14 Compositions and methods for transmucosal absorption
EP13804115.7A EP2861223B1 (en) 2012-06-15 2013-06-14 Compositions and methods for transmucosal absorption

Publications (1)

Publication Number Publication Date
SI2861223T1 true SI2861223T1 (sl) 2023-01-31

Family

ID=49758769

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201332010T SI2861223T1 (sl) 2012-06-15 2013-06-14 Sestavki in postopki za transmukozalno absorpcijo

Country Status (26)

Country Link
US (1) US20140171515A1 (sl)
EP (1) EP2861223B1 (sl)
JP (5) JP6259452B2 (sl)
CN (2) CN111388430A (sl)
AR (1) AR092330A1 (sl)
AU (2) AU2013274003B2 (sl)
BR (1) BR112014031394B1 (sl)
CA (2) CA2876902C (sl)
DK (1) DK2861223T3 (sl)
ES (1) ES2929133T3 (sl)
HK (1) HK1209361A1 (sl)
HR (1) HRP20221325T1 (sl)
HU (1) HUE060175T2 (sl)
IL (1) IL236268B (sl)
LT (1) LT2861223T (sl)
MX (2) MX2021005317A (sl)
MY (1) MY194495A (sl)
NZ (2) NZ631144A (sl)
PL (1) PL2861223T3 (sl)
PT (1) PT2861223T (sl)
RS (1) RS63822B1 (sl)
SG (2) SG11201408318RA (sl)
SI (1) SI2861223T1 (sl)
TW (3) TWI683660B (sl)
WO (1) WO2013188847A1 (sl)
ZA (1) ZA201500288B (sl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2501234T3 (pl) 2009-11-20 2018-01-31 Tonix Pharma Holdings Ltd Sposoby i kompozycje stosowane w leczeniu dolegliwości związanych z zespołem stresu pourazowego z użyciem cyklobenzapryny
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
DK2968992T3 (da) 2013-03-15 2020-02-03 Tonix Pharma Holdings Ltd Eutetiske formuleringer af cyclobenzaprinhydrochlorid og mannitol
SG11201701995PA (en) * 2014-09-18 2017-04-27 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride
KR20180035219A (ko) * 2015-07-15 2018-04-05 테라네수스 뇌의 헤미채널을 차단하기 위한 아미트리프틸린의 용도 및 이의 생체 내 효과 증진 방법
WO2018045367A1 (en) * 2016-09-02 2018-03-08 Nova Southeastern University Atropine sulfate rapidly-disintegrating sublingual tablets for treatment of acute organophosphate toxicity
CA3069699A1 (en) * 2017-07-13 2019-01-17 Tonix Pharmaceuticals Holding Corp. Analogs of cyclobenzaprine and amitryptilene
CN107519142B (zh) * 2017-08-24 2021-02-26 正大制药(青岛)有限公司 一种盐酸环苯扎林舌下片及其制备方法
CN107496355B (zh) * 2017-08-24 2021-04-30 正大制药(青岛)有限公司 一种盐酸环苯扎林舌下喷雾剂及其制备方法
ES2930376T3 (es) * 2017-12-08 2022-12-09 Hoffmann La Roche Formulación farmacéutica
SG11202004799TA (en) 2017-12-11 2020-06-29 Tonix Pharma Holdings Ltd Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
CN108721240A (zh) * 2018-06-08 2018-11-02 华益药业科技(安徽)有限公司 一种25mg阿米替林薄膜包衣片处方和工艺规程
MX2021002012A (es) 2018-08-20 2021-04-28 Tonix Pharma Holdings Ltd Metodos de tratamiento del trastorno por estres agudo y trastorno por estres postraumatico.
CA3156118A1 (en) * 2019-09-30 2021-04-08 Cadila Healthcare Limited INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CYCLOBENZAPRINE
JP2023521167A (ja) * 2020-04-08 2023-05-23 トニックス ファーマシューティカルズ ホールディング コーポレーション 性機能障害のシクロベンザプリン処置
EP4247370A1 (en) * 2020-11-20 2023-09-27 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for alcohol use disorder
EP4255407A1 (en) 2020-12-07 2023-10-11 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for fibromyalgia
WO2022170107A2 (en) 2021-02-04 2022-08-11 Tonix Pharmaceuticals Holding Corp. An improved method of assessing clinical response in the treatment of ptsd symptoms
WO2023059728A1 (en) 2021-10-06 2023-04-13 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients
WO2023250036A1 (en) 2022-06-21 2023-12-28 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for post-acute sequelae of (sars)-cov-2 infection (pasc)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
WO1999018937A1 (en) * 1997-10-16 1999-04-22 Merck & Co., Inc. New cyclobenzaprine composition
DK1077683T3 (da) * 1998-05-14 2003-03-31 Alza Corp Antidepressiv behandling
EP1202721A1 (en) 1999-08-13 2002-05-08 Vela Pharmaceuticals Inc. Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof
PT1202722E (pt) 1999-08-13 2005-11-30 L & L Technologies Llc Usos para o tratamento ou prevencao de disturbios do sono usando doses muito baixas de ciclobenzaprina
AU2001261744A1 (en) * 2000-05-19 2001-12-03 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
WO2002094229A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of muscle relaxants through an inhalation route
WO2004071491A1 (en) * 2003-02-04 2004-08-26 Chrysalis Technologies Incorporated Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem
US20090117054A1 (en) * 2005-03-29 2009-05-07 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
US20090148532A1 (en) * 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
JP2009079060A (ja) * 2008-10-15 2009-04-16 Novadel Pharma Inc 極性または非極性の、バッカルスプレーまたはカプセル
US20100266682A1 (en) * 2008-12-10 2010-10-21 Nipun Davar Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
PL2501234T3 (pl) * 2009-11-20 2018-01-31 Tonix Pharma Holdings Ltd Sposoby i kompozycje stosowane w leczeniu dolegliwości związanych z zespołem stresu pourazowego z użyciem cyklobenzapryny
US20110319389A1 (en) * 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
ITMI20110558A1 (it) * 2011-04-06 2012-10-07 Campiglio Consulting Srl Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale
DK2968992T3 (da) * 2013-03-15 2020-02-03 Tonix Pharma Holdings Ltd Eutetiske formuleringer af cyclobenzaprinhydrochlorid og mannitol

Also Published As

Publication number Publication date
JP2015519404A (ja) 2015-07-09
NZ631144A (en) 2016-12-23
WO2013188847A1 (en) 2013-12-19
DK2861223T3 (da) 2022-11-07
IL236268B (en) 2022-03-01
NZ726488A (en) 2018-10-26
AU2013274003A1 (en) 2015-02-05
JP6259452B2 (ja) 2018-01-10
TW201842903A (zh) 2018-12-16
CA3118913A1 (en) 2013-12-19
BR112014031394A8 (pt) 2021-11-03
BR112014031394A2 (pt) 2017-06-27
AU2018241128B2 (en) 2020-05-21
TWI683660B (zh) 2020-02-01
US20140171515A1 (en) 2014-06-19
MY194495A (en) 2022-11-30
AR092330A1 (es) 2015-04-15
LT2861223T (lt) 2022-12-12
PT2861223T (pt) 2022-11-07
CA2876902C (en) 2021-07-13
HRP20221325T1 (hr) 2022-12-23
TW201408281A (zh) 2014-03-01
AU2013274003B2 (en) 2018-07-05
MX2014015436A (es) 2015-07-14
JP2021138765A (ja) 2021-09-16
ES2929133T3 (es) 2022-11-25
CN111388430A (zh) 2020-07-10
SG11201408318RA (en) 2015-01-29
TWI590820B (zh) 2017-07-11
TW201731494A (zh) 2017-09-16
CA3118913C (en) 2024-04-30
AU2018241128A1 (en) 2018-10-25
JP2019123757A (ja) 2019-07-25
CN104684550A (zh) 2015-06-03
IL236268A0 (en) 2015-02-26
EP2861223B1 (en) 2022-08-03
MX2021005317A (es) 2022-12-16
HUE060175T2 (hu) 2023-02-28
PL2861223T3 (pl) 2022-12-12
EP2861223A1 (en) 2015-04-22
HK1209361A1 (en) 2016-04-01
JP2017222726A (ja) 2017-12-21
JP2024032964A (ja) 2024-03-12
TWI642429B (zh) 2018-12-01
EP2861223A4 (en) 2016-01-27
ZA201500288B (en) 2022-05-25
CA2876902A1 (en) 2013-12-19
WO2013188847A8 (en) 2015-02-05
SG10201605407TA (en) 2016-08-30
RS63822B1 (sr) 2023-01-31
BR112014031394B1 (pt) 2022-10-18

Similar Documents

Publication Publication Date Title
HK1209361A1 (en) Compositions and methods for transmucosal absorption
HK1214521A1 (zh) 用於治療蛋白質病的組合物和方法
EP2922861A4 (en) BIOMARKER COMPOSITIONS AND METHODS
EP2836212A4 (en) NOVEL COMPOSITIONS AND METHOD
EP2823306A4 (en) BIOMARKER COMPOSITIONS AND METHODS
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
GB201318361D0 (en) Content protection
HK1216250A1 (zh) '- '-羥基-二氫麥角胺化合物及組合物
GB201200707D0 (en) Composition
GB201315350D0 (en) Methods and compositions
GB201315347D0 (en) Methods and compositions
EP2878295A4 (en) COMPOSITION
EP2837670A4 (en) COMPOSITION CONTAINING FLUOROBIPHENYL
EP2910538A4 (en) AGENT COMPOSITION GENERATING GAS
EP2910537A4 (en) AGENT COMPOSITION GENERATING GAS
GB201222820D0 (en) Woolscouring method and composition
IL239426A0 (en) Methods and compositions of biomarkers
GB201206859D0 (en) Method and composition
ZA201500172B (en) Plant-disease-control composition and plant-disease-control method
RS56379B1 (sr) Kompozicija za zaštitu i uravnotežavanje kože
GB201222736D0 (en) Composition and process
GB201210989D0 (en) Composition and device
GB201222810D0 (en) Woolscouring method and composition
GB201204512D0 (en) Method and composition
GB201218322D0 (en) Herbal composition